Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight
1 other identifier
observational
175
1 country
14
Brief Summary
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered:
- 1.Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight?
- 2.Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2025
Shorter than P25 for all trials
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 11, 2025
CompletedFirst Submitted
Initial submission to the registry
November 23, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedFirst Posted
Study publicly available on registry
December 4, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2026
CompletedDecember 16, 2025
December 1, 2025
20 days
November 23, 2025
December 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients with ≥5% weight loss
day 0, 180
Secondary Outcomes (11)
Percent change in body weight from baseline
day 0, 90
Absolute change in body weight from baseline
day 0, 90
Percent change in body weight from baseline
day 0, 180
Absolute change in body weight from baseline
day 0, 180
Mean change in Body Mass Index from baseline
day 0, 90, 180
- +6 more secondary outcomes
Eligibility Criteria
Primary care clinic
You may qualify if:
- Male or female ≥18 years of age
- Willingness for signing and having signed the informed consent form
- BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity
You may not qualify if:
- Prior use of any GLP-1 agonist in the last 6 months
- Type 1 diabetes mellitus
- Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data
- Pregnancy or breast-feeding
- Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cinnagenlead
Study Sites (14)
Akbar Aliasgarzadeh Clinic
Tabriz, East Azerbaijan Province, Iran
Dr. Mohammadhossein Dabbaghmanesh Clinic
Shiraz, Fars, Iran
Behrang Motamed Clinic
Rasht, Gilan Province, Iran
Seyed Mojtaba Mehrdad Clinic
Rasht, Gilan Province, Iran
Mansoor Siavash Dastjerdi Clinic
Isfahan, Isfahan, Iran
Shokoofeh Bonakdaran Clininc
Mashhad, Khorasan Razavi, Iran
Sari Diabetes Research Center
Sari, Mazandaran, Iran
Alireza Esteghamati clinic
Tehran, Tehran Province, Iran
Farzad Hadaegh Clininc
Tehran, Tehran Province, Iran
Imam Khomeini Hospital
Tehran, Tehran Province, Iran
Iran University Endocrinology Research Center
Tehran, Tehran Province, Iran
Mohammadreza Mohajeri Tehrani Clininc
Tehran, Tehran Province, Iran
Khorshid Clinic
Yazd, Yazd Province, Iran
Hajieh Bibi Shahbazian Clinic
Ahvāz, Iran
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 23, 2025
First Posted
December 4, 2025
Study Start
November 11, 2025
Primary Completion
December 1, 2025
Study Completion
April 1, 2026
Last Updated
December 16, 2025
Record last verified: 2025-12